Fig. 4: Targeting EPC metabolism to enhance cancer immunotherapy. | npj Precision Oncology

Fig. 4: Targeting EPC metabolism to enhance cancer immunotherapy.

From: Targeting erythroid progenitor cell metabolism to enhance cancer immunotherapy

Fig. 4: Targeting EPC metabolism to enhance cancer immunotherapy.The alternative text for this image may have been generated using AI.

Metabolic reprogramming of EPCs can be targeted to reverse immunosuppressive effects, thereby potentiating the efficacy of various cancer treatment strategies, including radiotherapy and immunotherapy. EPC erythroid progenitor cell, HPSC hematopoietic stem cell, ROS reactive oxygen species, ARG arginase, EDMC erythroid-derived myeloid cell, CCL5 c-c motif chemokine ligand 5, CCR5 c-c motif chemokine receptor 5, TME tumor microenvironment.

Back to article page